-
Siolta Therapeutics Raises $12 Million in Series C Financing for Clinical Development
3.13.2024WilmerHale represented Siolta Therapeutics, Inc., a biotech company developing live biotherapeutics that target the core drivers of disease, in its $12 million Series C Preferred Stock financing.
-
Recent Venture Financings as Company Counsel: 2024
2.16.2024In 2023, we served as counsel in more than 150 venture financings raising over $4 billion, including some of the largest and most prominent deals of the year.
-
WilmerHale Advises Investors in Nasdaq Private Market Series B Financing
2.12.2024On February 8, 2024, Nasdaq Private Market, a leading provider of liquidity solutions to private companies, announced that it had closed its Series B financing.
-
WilmerHale Advises TômTex in Series Seed Preferred Stock Financing
1.18.2024WilmerHale recently represented TômTex Inc., a sustainable manufacturing company that develops naturally biodegradable textiles that mimic materials like leather and suede, in its Series Seed Preferred Stock financing.
-
WilmerHale Advises Air Space Intelligence in $34M Series B Financing
12.13.2023WilmerHale recently advised Air Space Intelligence, a modern aerospace company addressing the software crisis across commercial and government sectors, in its Series B funding round.
-
Cornell University, WilmerHale Collaborate to Publish Startup Launch Booklet for Entrepreneurs and Founders of Emerging Companies
11.28.2023Together, WilmerHale and Cornell University have collaborated in a joint effort to publish Startup Launch – Liftoff with Legal 101 for Entrepreneurs, a booklet for startup founders to think early about key items that will set them off on the right legal track.
-
Best Practices For Defense Tech Startup Financing
11.27.2023In an expert analysis published by Law360, Partners Stephanie Evans, Gary Schall and Jason Chipman deep-dive into the best practices for defense technology startups to consider when navigating the expanding defense tech subsector of the emerging company ecosystem.
-
WilmerHale Advises DTCC in its Investment in Fnality
11.17.2023WilmerHale recently represented Depository Trust & Clearing Corporation (DTCC) in its investment in Fnality, a wholesale digital cash payment system that will support tokenized, peer-to-peer markets.
-
WilmerHale Advises Aleph on Series A Financing
10.26.2023On October 24, 2023, Aleph, a next-gen financial planning and analysis company, announced its Series A financing round as it emerged from stealth mode.
-
WilmerHale Advises Hawkeye 360 in Series D-1 Preferred Stock Financing
10.18.2023On October 18, 2023, HawkEye 360, Inc. announced the subsequent closing of its Series D-1 Preferred Stock financing, which was comprised of approximately $10 million.
-
WilmerHale Advises Glass Health in $5M Seed Round
10.6.2023On September 11, 2023, Glass Health, an AI-Powered clinical decision support platform, announced its $5 million seed round led by Initialized Capital.
-
WilmerHale Advises Sierra Space in $290M Series B Financing
10.3.2023Sierra Space, a leading pureplay commercial space company building the first end-to-end business and technology platform in space, announced the completion of a $290 million Series B funding round.
-
WilmerHale Named Venture Capital Firm of the Year by LMG Life Sciences
9.12.2023LMG Life Sciences has named WilmerHale as the Venture Capital Firm of the Year in its 11th annual awards.
-
WilmerHale Advises Georgiamune on $75M Series A Financing
8.14.2023On August 9, 2023, Georgiamune Inc., a privately held, clinical stage biotechnology company, announced the clearance of its Investigational New Drug application by the US Food and Drug Administration for GIM-122, a dual-functioning monoclonal antibody.
-
WilmerHale Advises HawkEye 360 in $58M Series D-1 Financing
7.14.2023On July 13, 2023, HawkEye 360, Inc., the world's leading defense technology company for space-based radio frequency data and analytics, announced it has closed $58 million in new funding in a Series D-1 financing.